Journal Information
Vol. 29. Issue. 6.December 2009
Pages 503-617
Vol. 29. Issue. 6.December 2009
Pages 503-617
Full text access
Clinical and microbiological aspects of fungal peritonitis in peritoneal dialysis
Aspectos clínicos y microbiológicos de la peritonitis fúngica en diálisis peritoneal
Visits
21150
Rebeca García Agudoa, P.. García-Martosb
a Sección de Nefrología, Complejo Hospitalario La Mancha-Centro, Alcázar de San Juan, Ciudad Real, España,
b Servicio de Microbiología y Parasitología, Hospital Universitario Puerta del Mar, Cádiz, Cádiz, España,
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Peritonitis is one of the most serious complications of peritoneal dialysis. Pathogenic bacteria cause the majority of cases of peritonitis. Fungal infection is rare but it is associated with high morbidity, the inability to continue on the dialysis program and a high mortality rate. Its incidence ranges from 4% to 10% of all peritonitis episodes in children and from 1% to 23% in adults. Its clinical presentation is similar to bacterial peritonitis. Until now, predisposing factors of fungal peritonitis have not been clearly established; the history of bacterial peritonitis episodes and treatment with broad-spectrum antibiotics have been often reported in literature. Candida species were the most common pathogens and Candida albicans was the most frequent, but high prevalence of Candida parapsilosis has been observed in the last decade. Microbiological findings are essential to determine the etiology of peritonitis. Successful management of fungal peritonitis requires antifungal therapy, the removal of the peritoneal catheter and the subsequent transfer to hemodialysis. Fluconazole and amphotericin B are recommended as antifungal agents. New drugs such as voriconazole and caspofungin are very effective. The aim of this systematic review has been to analyse the clinical and microbiological aspects of fungal peritonitis, as they are not well known and have changed in the last few years.
Keywords:
Voriconazole
Keywords:
Fluconazole
Keywords:
Antifungal therapy
Keywords:
Peritoneal catheter
Keywords:
Candida
Keywords:
Peritoneal dialysis
Keywords:
Fungal peritonitis
Keywords:
Peritonitis

La peritonitis es una de las complicaciones más graves de la diálisis peritoneal. Las bacterias son las responsables de la mayoría de los casos. La infección fúngica es infrecuente, pero se asocia con una alta morbilidad, con la imposibilidad de continuar en el programa de diálisis y con un importante índice de mortalidad. Su incidencia varía del 1% al 10% de los episodios de peritonitis en niños y del 1% al 23% en adultos. Su presentación clínica es similar a la de la peritonitis bacteriana. Los factores predisponentes de peritonitis fúngica no han sido establecidos con claridad; los episodios previos de peritonitis bacteriana y el tratamiento con antibióticos de amplio espectro han sido descritos a menudo en la literatura. Las especies de Candida son los patógenos más habituales y Candida albicans la más frecuente, pero en la última década se ha observado una alta prevalencia de Candida parapsilosis. El diagnóstico microbiológico es fundamental para determinar la etiología y prescribir el tratamiento, que suele requerir, además de la terapia antifúngica, la retirada del catéter peritoneal y la consecuente transferencia a hemodiálisis. Fluconazol y anfotericina B son los antifúngicos recomendados; los nuevos fármacos como voriconazol y caspofungina han demostrado tener también una gran utilidad. El propósito de esta revisión sistemática ha sido analizar los aspectos clínicos y microbiológicos de la peritonitis fúngica, los cuales son poco conocidos y han cambiado en los últimos años.

Palabras clave:
Voriconazol
Palabras clave:
Fluconazol
Palabras clave:
Antifúngicos
Palabras clave:
Catéter peritoneal
Palabras clave:
Candida
Palabras clave:
Diálisis peritoneal
Palabras clave:
Peritonitis fúngica
Palabras clave:
Peritonitis
Full Text

INTRODUCTION

Peritonitis is one of the most serious and frequent complications in patients undergoing kidney replacement therapy with peritoneal dialysis, especially in continuous ambulatory peritoneal dialysis. Patients treated with peritoneal dialysis are exposed to infections due to unnatural communication with the exterior through the peritoneal catheter and the repeated introduction of more or less biocompatible solutions into the peritoneal cavity. Repeated peritonitis episodes may lead to irreversible damage to the peritoneal membrane, which may require suspending the technique and transferring the patient to haemodialysis.

Bacterial infection is responsible for approximately 80% of peritonitis episodes associated with peritoneal dialysis. Fungal infection is an uncommon complication which mostly occurs in patients who have been undergoing dialysis for an extended period of time; it does not normally arise as a first episode. The exceptional nature of fungal peritonitis has made it difficult to establish general action criteria, since the low number of episodes that authors usually describe in their series does not permit us to extrapolate results.

In this study, we will use a systematic review to analyse articles on fungal peritonitis that have been published in the literature. The objective is to extract conclusions that will provide us with a better understanding of this clinical condition.

MATERIAL AND METHODS

The clinical research articles that we reviewed were selected among those published in the last three decades. They include original studies, reviews, clinical cases and letters to the editor regarding fungal peritonitis in patients undergoing peritoneal dialysis treatment. We used two sources for the bibliographical search: firstly, the Ovid Technologies platform which contains nearly all of the existing databases (Medline, Embase, Current Contents, Cinahl, Inspec, Psycinfo, etc.) and enables us to consult a large number of full-text articles, and secondly, the PubMed search engine developed by the National Center for Biotechnology Information, which provides access to the bibliographic databases compiled by the National Library of Medicine. In addition, we consulted other habitual sources: EBSCO Open Journals, Proquest Medical Library, Science Direct, Springer Links and Wiley Interscience.

We used the following search terms: fungal peritonitis, peritoneal dialysis, continuous ambulatory peritoneal dialysis, Candida, Cryptococcus, Geotrichum, Saccharomyces, Malassezia, Pichia, Rhodotorula, Trichosporon, Blastomyces, Coccidioides, Paracoccidioides, Histoplasma, Acremonium, Alternaria, Aspergillus, Aureobasidium, Beauveria, Bipolaris, Chaetomium, Chrysonilia, Chrysosporum, Cladophialophora, Cladosporium, Curvularia, Drechslera, Emmonsia, Exophiala, Fonsecaea, Fusarium, Natrassia, Onychocola, Paecilomyces, Penicillium, Phialemonium, Phialophora, Rhamichloridium, Rhinocladiella, Scedosporium, Scopulariopsis, Scytalidium, Sporothrix, Trichoderma, Absidia, Cunninghamella, Mucor, Rhizomucor, Rhizopus, Syncephalastrum.

Based on the resulting bibliography, we gathered information on the epidemiology and pathogeny of the fungal peritonitis, the risk factors for its development, the distribution of aetiological agents (both yeasts and filament fungus) responsible for peritonitis episodes, the clinical manifestations, the microbiology diagnostic techniques and the therapeutic options.

EPIDEMIOLOGY AND RISK FACTORS

Fungal peritonitis in peritoneal dialysis is an infrequent complication. Its incidence rate is similar in automated peritoneal dialysis and continuous ambulatory peritoneal dialysis, although with the automated technique, the lower number of connections can reduce the episodes. Fungi penetrate the peritoneal cavity through intraluminal or periluminal pathways and cross the intestinal mucosa, or enter through the haematogenic pathway due to a distant fungal infection.

Although fungal infection makes up about 4-10% of the peritonitis cases in children and 1-23% of those in adults according to the series,1-18 resulting in an average of 4-6% of all peritonitis episodes, it has a worse prognosis than a bacterial infection does. This is because a fungal infection favours catheter obstruction, abscess formation and the development of peritonitis.3,4,7,8,10,19-23 A mortality rate of 5-53% has been reported for patients with this condition and a technique failure rate of 40-55%, which forces us to discontinue peritoneal dialysis and transfer patients to haemodialysis.1,4,9,10,12,13,19,23-27

Risk factors for developing fungal peritonitis have not been clearly determined. Numerous situations have been listed which play an important role in the appearance of the mycotic infection, including previous episodes of bacterial peritonitis and wide-spectrum antibiotic treatment. Often, more than one risk factor is identified in patients. Table 1 shows the most frequently described risk factors.

Patients with fungal peritonitis present a higher rate of bacterial peritonitis episodes than patients without FP,2,5,10,11,13,14,20,23,28-31 sometimes more than two times higher,8,14,23 owing to the fact that the peritoneal inflammation can increase susceptibility to a fungal invasion. It has been suggested that fungal infection appears most of all after episodes of bacterial peritonitis due to gram-negative bacilli.16,27 The administration of wide-spectrum antibiotics in previous months, generally as a treatment for bacterial peritonitis episodes, is closely related to the appearance of fungal peritonitis, and is indicated in 30-95% of the episodes described in the literature,1-4,7-11,13-16,18,23,25,26,29,30 although the absence of prior antimicrobial therapy does not exclude the possibility of infection.15 In cases of peritonitis due to environmental fungus filaments, it seems that the use of antibiotics does not play such an important role.13

Other listed risk factors are prolonged time in the peritoneal dialysis programme and the time elapsed from insertion of the peritoneal catheter.3-5,8,12,30 Maintaining the catheter after detecting the fungal infection is related to a worse prognosis, and on some occasions has been the main factor causing failure of the technique and mortality.8,12,13,15,18,25,26

Advanced age has been cited on various occasions as a noteworthy trait in patients with fungal peritonitis.6,8,14,26,30,31 Similarly, the administration of immunosuppressants such as corticoids1,15 and the presence of immunocompromising or debilitating diseases, such as systemic lupus erythematosus27,32 or HIV33 are cited as risk factors. Diabetes mellitus in particular is identified as a risk factor in 30-65% of all episodes,7,13-15,19,23,25,26,31 although it is also frequently present with bacterial peritonitis. Hospitalisation is considered to be a risk factor when an infection of nosocomial origin occurs, as is the coexistence of an extraperitoneal fungal infection that causes a peritoneal infection through a haematogenic pathway.14,29

On the other hand, no significant differences are observed with respect to sex, as some authors cite higher incidence rates in females31,34 and others in males.26 Neither the renal failure aetiology (due to a vascular cause, glomerulonephritis, diabetic nephropathy, tubulointerstitial nephropathy, renal polycystosis, others), the cardiovascular comorbidity (arrhythmias, ischaemic heart disease, cerebral vascular disease, peripheral vascular disease) nor the season of the year8,35 have been linked to the condition.

AETIOLOGICAL AGENTS

Infectious peritonitis in patients who undergo peritoneal dialysis is commonly caused by bacteria. The most common agents are coagulase-negative Staphylococcus and Staphylococcus aureus, followed by Streptococcus, Enterococcus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae; other bacteria are occasionally involved. In some cases, aetiology is mixed (bacterial and fungal) or polymicrobial.13,36-38 The aetiology of fungal peritonitis, however, is very diverse and includes most yeast species and human pathogenic fungal filaments, as well as other environmental yeasts and fungi that are uncommon in clinical practice.

YEASTS

Yeasts are widely distributed in nature, as these organisms are capable of living in extraordinary environmental conditions. Of the approximately 500 known species, only about 25 or 30 were considered pathogens a few years ago, but recently their number has grown considerably. Table 2 lists the yeasts that are implicated in peritonitis episodes in patients undergoing peritoneal dialysis.

Strains of the genus Candida have the highest incidence rate in fungal peritonitis in peritoneal dialysis, and are responsible for about 60-90% of all cases.1,4,15,19,20,23,30,31,34 Candida albicans has classically been considered the predominant species. In recent years, C. parapsilosis, which habitually colonises the skin and has a proven ability to adhere to synthetic materials, has at times been implicated as much or more than C. albicans1,4,15,19,20,23,30,31,34 and its presence is associated with a poorer prognosis and the need for a more aggressive treatment.4,20,39 Currently, we can state that C. parapsilosis is the most common pathogen in fungal peritonitis in patients undergoing peritoneal dialysis.

The incidence rates for other Candida species are not wellestablished because the species is not identified in many cases and only listed as Candida sp. Over the last decade, the number of non-albicans species has been growing and their involvement has become associated with increased mortality, given that some are resistant to the usual antifungals used in treatment.1,2,4-6,8,9,13,15,19,21,23,28,30,31,34,40-49

The literature did not reveal any cases of infection with C. krusei, which has a natural resistance to fluconazole.

Other peritonitis-causing yeasts are exceptional and have only been cited in a few episodes. There are some published cases of peritoneal infection as a manifestation of systemic infection with Cryptococcus neoformans43,50,51 and another case due to C. laurentii.52 The Trichosporon genus is a more constant peritoneal pathogen, whether we refer to the 56-58 species T. beigelii,31,53-55 the only one that was recognised a few years ago, or some of the new species (T. inkin, cutaneum,30,59 T. asahii30,60). While the Rhodotorula genus rarely causes infections in humans, there have been cases of peritonitis due to R. mucilaginosa (previously known as rubra),15,16,30,61-63 R. glutinis64 and R. pilimanae.6 We have also found isolated cases of peritoneal infection due to Pichia ohmeri65 and Geotrichum sp.,66 as well as Malassezia furfur,67 a lipophilic yeast that causes pityriasis versicolor, and Malassezia pachydermatis,68 an inhabitant of the external ear canal in canids.

Some dimorphic fungi, with yeast-like and filament morphology, have occasionally been described in peritonitis with peritoneal dialysis: Histoplasma capsulatum69,70 and Coccidioides immitis,71 both of which are pathogens, and Blastobrotys proliferans,72 which is never mentioned in human infections.

FILAMENTOUS FUNGI

Filamentous fungi or moulds, like yeasts, are widely found in nature. They are described in peritonitis at a much lower percentage than yeasts are, but their involvement is growing, and in some series makes up 40% of cases.26 The fact that these fungi are more resistant to antifungals has sparked special clinical interest. The listed genera and species are quite varied and include hyaline, dematiaceous and zygomycete fungi; some are related to human infections and other saprophytes have only rarely been described in clinical studies. Table 3 lists the filamentous fungi that have been involved in fungal peritonitis with peritoneal dialysis.

Despite the fact that the Aspergillus genus is one of the most frequent in clinical practices, cases of peritoneal infection are not very numerous.6,13,22,,26,34,35,64,73-83 Penicillium is referred to on several occasions, but without listing the species.26,38,84-87

Episodes of peritonitis due to Paecilomyces are detected quite rarely.6,88-94 The genera Acremonium and Fusarium are also of special interest due to their resistance to antifungals.6,23,26,34,90,95-102 The so-called black yeasts of the Exophiala genus have also been implicated in peritoneal infection cases94,103-107 as well as the Curvularia genus which rarely causes disease in humans.53,108-111

Other filamentous fungi are less common in peritonitis cases in patients undergoing peritoneal dialysis. Some are known as opportunistic pathogens: Alternaria,112,113 Bipolaris,114,115 Aureobasidium pullulans,116,117 Scedosporium apiospermum,118 Scopulariopsis sp.,119 Cladosporium sp.26 and Madurella mycetomatis.30 Others are less commonly reported as pathogens: Trichoderma,90,120-122 Chaetomium globosum,123 Chrysonilia sitophila,123 Lecythophora mutabilis,124 Hormonema dematioides,125 and Verticillium sp.126

Zygomycetes are fungi that are uncommon as peritonitis agents in patients undergoing peritoneal dialysis, but they are associated with a high mortality rate due to their lack of response to antifungals.78 Cases of peritonitis due to Rhizopus sp.16,127,128,78,129,130 and Cuninghamella26,131 have been reported.

CLINICAL MANIFESTATIONS

From a clinical viewpoint, fungal peritonitis is indistinguishable from bacterial peritonitis; both present symptoms of abdominal pain, and less frequently, fever, nausea, vomiting, diarrhoea, worsened general state and cloudy peritoneal effluent. The diagnosis is carried out by a biochemical analysis of the peritoneal liquid when a count of 100 leukocytes or higher per microlitre is detected where at least 50% are polymorphonuclear, but microbiological analysis is necessary in order to establish the fungal etiology.15 We must be mindful that the liquid can sometimes offer a low count if it has been in the peritoneal cavity for less than two hours; a predominance of polymorphonuclear cells can indicate infection in these cases. As fungemia is rarely present, there is usually no systemic leukocytosis.

We can suspect an episode of fungal peritonitis when there are recurring episodes of bacterial peritonitis and a lack of response to antibiotic treatment. Among the analytic data associated with fungal infection, only the following have been described as significant: the presence of anaemia and a plasma albumin drop below 3g/dl, and occasionally, eosinophilia in the dialysate.8,14,52,71,75,77 Hypoalbuminaemia can be explained by the lack of ultrafiltration that takes place during the peritonitis episode, or by the increase in peritoneal loss of proteins. This factor has been linked to a poorer prognosis,18 although the prognostic factors for fungal peritonitis are not clearly defined. Maintaining the peritoneal catheter and the presence of ileus and abdominal pain seem to imply increased mortality.4,7

MICROBIOLOGICAL DIAGNOSIS

The microbiological diagnosis is based on microscope viewing or on isolating fungal cultures from the peritoneal dialysate. In general, particularly in the case of environmental fungi, we must demonstrate their presence in more than one sample to be able to confirm their participation as an agent causing peritonitis; these fungi are contaminants that are frequently isolated in cultures.131

The laboratory should receive 50-100ml of peritoneal fluid, of which 10ml are inoculated in aerobic and anaerobic blood culture bottles and left to incubate over seven days at 35-37º C. The rest is centrifuged at 3000rpm during 15 minutes. Using the sediment, we then proceed to direct microscopic viewing of both fresh and the stained samples. At the same time, we inoculate the sample in general and specific culture media to examine for bacteria and fungi. In a clear case of suspected fungal peritonitis, the culture medium CHROMagar Candida can be added, which is extremely useful for differentiating yeasts.34

The direct microscopic observation and the Gram stain have highly variable sensitivities between 10 and 70% according to different authors, but they are higher than those for bacterial peritonitis.6,13,26 Despite their dubious results, they are effective in the early detection of fungal elements, which makes it possible to consider removing the peritoneal catheter and establish a specific treatment.13,25 The microbiological culture has a sensitivity of nearly 100% and allows us to identify the species of the infection-causing agent. Yeasts are identified by their morphological, biochemical and nutritional characteristics, fundamentally by the their pattern of carbon compound assimilation, for which we use commercial systems such as ID 32C (bioMérieux, France) and others.13 Filamentous fungi, however, are identified exclusively by their growth time, the morphological characteristics of the colony (size, colour, texture, borders, diffusible pigment) and their microscopic characteristics (hyphae, phialides, conidiophores, conidia). Currently, serological diagnostic techniques are available to us, such as the detection of the Aspergillus galactomannan antigen, as well as molecular DNA sequencing techniques for identifying yeasts and filamentous fungi.132,133

Determining the antifungal sensitivity of fungi that produce peritonitis is not done systematically, except in the case of a few species known to be resistant or in the case of treatment failure. At present, we recognise the importance of determining the sensitivity of some yeast species to azolic compounds, as the development of resistant strains has been reported.6

TREATMENT

Treatment of fungal peritonitis is not clearly defined due to the low number of patients treated in the series we reviewed and the use of different antifungals, routes of administration, dose and treatment duration.

Recommendations by the International Society for Peritoneal Dialysis in 2005 and by the Spanish Society of Nephrology (SEN) in 2006 state that in addition to antifungal treatment, early removal of the catheter is fundamental to resolving the condition.25,134 It has been shown that symptoms persist up to 72 hours after administering antifungals in a large number of episodes. This is due in part to the ability fungi to form biofilms on the surface of catheters, which decreases the penetration of the drugs. It is therefore accepted that catheter removal is necessary in order to eradicate the infection, given that it is a primordial site for microbial colonisation; however, the best time to do so is not clear. Some authors recommend removing the catheter in the first 24 hours after administering the antifungal treatment and others recommend removal even without having administered treatment, stating that the mortality rate increases if the catheter is removed after 24 hours.5,8,9,13,15,18,25,26 The reinsertion of a new peritoneal catheter, where applicable, should be performed at least 4-6 weeks after the condition is resolved.1,9,26

In addition to the removal of the catheter, all protocols must include the administration of antifungal drugs by the peritoneal, oral or intravenous route. Treatment options for fungal peritonitis were limited up until the appearance of the new amphotericin B formulations, wide-spectrum triazoles and echinocandins, which are safer and have a better pharmacokinetic profile. At present, the antifungals available on the market include polyenes (amphotericin B), azolic derivatives (miconazole, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, ravuconazole, isavuconazole), fluorated pyrimidines (fluorocytosine) and echinocandins (caspofungin, micafungin, anidulafungin). In isolated cases, terbinafin (from the allylamine group) has been used: this antifungal acts on dermatophyte fungi, C. albicans and Malassezia.92

Fluconazole has been considered the treatment of choice for years, due to its excellent penetration in the peritoneum, good bioavailability, the few adverse reactions that it provokes, and the possibility of administering it to patients on an outpatient basis.135 It has even been stated that treatment with oral fluconazole and the removal of the peritoneal catheter would be as effective as associating intraperitoneal fluconazole and oral 5-fluorocytosine.24 It is known that this antifungal is not effective for many of the filamentous fungi that cause peritonitis, especially Aspergillus and Fusarium. On the other hand, in recent years we have confirmed the appearance of Candida species that are resistant to fluconazole (C. krusei, C. ciferrii, C. norvegensis, C. glabrata, C. famata, C. lusitaniae, C. guilliermondii and C. tropicalis), as are other yeasts (Trichosporon), which indicates that it is not convenient to use fluconazole in monotherapy for certain peritonitis episodes, and that its effectiveness must be evaluated for some yeast species.25 The new triazoles, particularly voriconazole, are extremely useful in fungal peritonitis, whether by the oral or intravenous route, and even permit us to maintain the peritoneal catheter.73,136,137

Amphotericin B is a wide-spectrum antifungal drug; resistance has only been detected in vitro in a few species of yeasts and filamentous fungi, so it offers a certain amount of safety.46 One of its drawbacks is that intraperitoneal administration causes local irritation and does not enable it to reach a good inhibitory concentrations, which is why it is used intravenously.135,136 The liposomal formulation offers reduced toxicity without decreasing effectiveness. Primary resistance to amphotericin B has emerged in parallel with an increase in infections caused by certain yeasts (Trichosporon beigelii, C. lusitaniae, C. guilliermondii), hyaline filamentous fungi (Fusarium, Scopulariosis, Scedosporium) and some dematiaceous fungi.

Echinocandins are able to act upon biofilms, which could be another argument for their therapeutic indication in treating catheter-associated infections. They are administered by intravenous perfusion. Caspofungin is the most widely used, but its analogue anidulafungin is two to four times more active in vitro. The most important disadvantage of using chinocandins is that there is no method of reference for evaluating their in vitro activity on yeasts and filamentous fungi; for that reason, we must be prudent when extrapolating in vivo data.

The antifungal drugs currently used in clinical practice include the following: fluconazole (whether associated with 5-fluorocytosine or not), amphotericin B, voriconazole and caspofungin, either as monotherapy or in any of their possible combinations.4,9,28-30,90 Although monotherapy with fluconazole (200mg/day) is generally effective, combined treatment or use of more potent drugs can improve the prognosis and decrease mortality.100 For this reason, it is recommended in the event of treatment failure, resistance or intolerance to other antifungal drugs and episodes caused by filamentous fungi.13,25,29,56,138 Combined treatment with fluconazole allows us to reduce the dose to 100mg/day and reduce treatment time, which should generally be a minimun of 2 weeks minimum up to 4-6 weeks, according to different authors.

The usefulness of administering oral prophylactic treatment with fluconazole (100mg/day), ketoconazole (200mg/day) and nystatin (daily rinse) has been demonstrated for avoiding fungal proliferation in those patients with a high risk of infection due to prolonged antibiotic treatment, repeated peritonitis episodes or compromised immune systems.9,35,139-142 However, some studies do not confirm a decrease in fungal peritonitis episodes with the use of nystatin as a prophylactic.143-145

Some studies have shown a decrease in the bacterial peritonitis incidence rate with the new advances in peritoneal dialysis systems, the use of more biocompatible solutions (with no glucose degradation products and with bicarbonate or low lactate concentrations),138 our better understanding of risk factors and the use of preventative measures, but there is no data regarding fungal infection. It is possible that this fact, together with the early removal of the peritoneal catheter and the use of potent antifungal drugs, is a major contribution to the decrease in fungal peritonitis episodes in peritoneal dialysis patients.

Table 2. Dimorphic yeasts and fungi causing peritonitis in peritoneal dialysis

Table 1. Risk factors associated with peritonitis in peritoneal dialysis

Table 3. Filamentous fungi causing peritonitis in peritoneal dialysis

Bibliography
[1]
Goldie SJ, Kiernan-Troidle L, Torres C, Sorban-Brennan N, Dunne D, Kliger AS, et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 1996;1:86-91.
[2]
Bren A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1998;17:839-43. [Pubmed]
[3]
The Turkish Multicenter Peritoneal Dialysis Study Group (TULIP). The rate, risk factors, and outcome of fungal peritonitis in CAPD patients: experience in Turkey. Perit Dial Int 2000;20:338-40.
[4]
Wang AY, Yu AW, Li PK, Lam PK, Leung CB, Lai KN, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000;36:1183-92. [Pubmed]
[5]
Troidle L, Gorban-Brennan N, Kliger A, Finkelstein FO. Continous peritoneal dialysis-associated peritonitis: a review and current concepts. Semin Dial 2003;6:428-37.
[6]
Bibashi E, Memmos D, Kokolina E, Tsakiris D, Sofianou D, Papadimitriou M. Fungal peritonitis complicating peritoneal dialysis during an 11-year period: report of 46 cases. Clin Infect Dis 2003;36:927-30.
[7]
Prasad KN, Prasad N, Gupta A, Sharma RK, Verma AK, Ayyagari A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: a single centre Indian experience. J Infect 2004;48:96-101. [Pubmed]
[8]
Molina P, Puchades MJ, Aparicio M, García Ramón R, Miguel A. Experiencia en peritonitis fúngica en una unidad de diálisis durante diez años. Nefrología 2005;25:393-8. [Pubmed]
[9]
Prasad, N, Gupta, A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005;25:207-22. [Pubmed]
[10]
Ekim M, Fitöz S, Yagmurlu A, Ensari A, Yüksel S, Acar B, et al. Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients. Nephrology (Carlton) 2005;10:341-3.
[11]
Das R, Vaux E, Barker L, Naik R. Fungal peritonitis complicating peritoneal dialysis: report of 18 cases and analysis of outcomes. Adv Perit Dial 2006;22:55-9. [Pubmed]
[12]
Felgueiras J, Del Peso G, Bajo A, Hevia C, Romero S, Celadilla O, et al. Risk of technique failure and death in fungal peritonitis is determined mainly by duration on peritoneal dialysis: single-center experience of 24 years. Adv Perit Dial 2006;22:77-81. [Pubmed]
[13]
Predari SC, De Paulis AN, Verón D, Zucchini A, Santoianni JE. Fungal peritonitis in patients on peritoneal dialysis: twenty five years of experience in a teaching hospital in Argentina. Rev Argent Microbiol 2007;39:213-7. [Pubmed]
[14]
Kocak Z, Bulut C, Kinikli S, Yilmaz GR, Irmak H, Demdroz AP. Fungal peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of three cases. Turk Med J 2007;1:30-3.
[15]
Rosa NG, Silva S, Lopes JA, Branco P, De Almeida E, Ribeiro C, et al. Fungal peritonitis in peritoneal dialysis patients: Is previous antibiotic therapy an essential condition? Mycoses 2007;50:79-81. [Pubmed]
[16]
Raaijmakers R, Schröder C, Monnens L, Cornelissen E, Warris A. Fungal peritonitis in children on peritoneal dialysis. Pediatr Nephrol 2007;22:288-93. [Pubmed]
[17]
Hooman N, Madani A, Sharifian Dorcheh M, Mahdavi A, Derakhshan A, Gheissari A, et al. Fungal peritonitis in Iranian children on continuous ambulatory peritoneal dialysis: a national experience. Iran J Kidney Dis 2007;1:29-33. [Pubmed]
[18]
Ram R, Swarnalatha G, Neela P, Murty KV. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: a single-centre experience in India. Nephron Clin Pract 2008;110: 207-12.
[19]
Wong PN, Mak SK, Lo KY, Tong GM, Wong AK. A retrospective study of seven cases of Candida parapsilosis peritonitis in CAPD patients: the therapeutic implications. Perit Dial Int 2000;20:76-9. [Pubmed]
[20]
Chen KH, Chang CT, Yu CC, Huang JY, Yang CW, Hung CC. Candida parapsilosis peritonitis has more complications than other Candida peritonitis in peritoneal dialysis patients. Ren Fail 2006;28:241-6. [Pubmed]
[21]
Gupta A, Mi H, Wroe C, Jaques B, Talbot D. Fatal Candida famata peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. Nephrol Dial Transplant 2006;21:2036-7. [Pubmed]
[22]
Liu SW, Chern CH, Yen DH, Huang CI, How CK. Abdominal wall and intraperitoneal abscesses complicating Aspergillus peritonitis in peritoneal dialysis. Am J Med Sci 2009;337:56. [Pubmed]
[23]
García-Martos P, Gil de Sola F, Marín P, García-Agudo L, García-Agudo R, Tejuca F, et al. Peritonitis fúngica en diálisis peritoneal continua ambulatoria: descripción de 10 casos. Nefrología 2009;29(6):534-9. [Pubmed]
[24]
Chan TM, Chan CY, Cheng SW, Lo WK, Lo CY, Cheng IK. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. Nephrol Dial Transplant 1994; 9: 539-42. [Pubmed]
[25]
Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. ISPD guidelines/recommendations. Peritoneal dialysisrelated infections: 2005 update. Perit Dial Int 2005;25:107-31.
[26]
Indhumathi E, Chandrasekaran V, Jagadeswaran D, Varadarajan M, Abraham G, Soundararajan P. The risk factors and outcome of fungal peritonitis in continuous ambulatory peritoneal dialysis patients. Indian J Med Microbiol 2009;27:59-61. [Pubmed]
[27]
Huang JW, Hung KY, Wu KD, Peng YS, Tsai TJ, Hsieh BS. Clinical features of and risk factors for fungal peritonitis in peritoneal dialysis patients. J Formos Med Assoc 2000;99:544-8. [Pubmed]
[28]
Kaitwatcharachai C. Candida parapsilosis peritonitis in patients on CAPD. Mycopathologia 2002;154:181-4. [Pubmed]
[29]
Fourtounas C, Marangos M, Kalliakmani P, Savidaki E, Goumenos DS, Vlachojannis JG. Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy. Nephrol Dial Transplant 2006;21:236-7. [Pubmed]
[30]
Chen CM, Ho MW, Yu WL, Wang JH. Fungal peritonitis in peritoneal dialysis patients: effect of fluconazole treatment and use of the twin-bag disconnect system. J Microbiol Immunol Infect 2004;37:115-20. [Pubmed]
[31]
Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, et al. Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008;28:155-62. [Pubmed]
[32]
Schattner A, Kagan A, Zimhony O. Aspergillus peritonitis in a lupus patient on chronic peritoneal dialysis. Rheumatol Int 2006;26:762-4. [Pubmed]
[33]
Anuradha S, Chatterjee A, Bajaj J, Singh NP, Agarwal SK, Kaur R. Trichosporon beigelii peritonitis in a HIV-positive patient on continuous ambulatory peritoneal dialysis. J Assoc Physicians India 2000;48:1022-4. [Pubmed]
[34]
Manzano-Gayosso P, Hernández-Hernández F, Méndez-Tovar LJ, González-Monroy J, López-Martínez R. Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD). Mycoses 2003;46:425-9. [Pubmed]
[35]
Morey A, Lima C, Matas B, Munar MA. Profilaxis con fluconazole de las peritonitis fúngicas en diálisis peritoneal. Nefrología 2001;21:608. [Pubmed]
[36]
Olea T, Hevia C, Bajo MA, Del Peso G, Selgas R. Peritonitis por Pasteurella multocida y Candida albicans. Nefrología 2006;26:136-8. [Pubmed]
[37]
Janakiraman H, Abraham G, Mathew M, Lalitha MK, Bhaskar S. Relapsing peritonitis due to co-infection with Mycobacterium triviale and Candida albicans in a CAPD patient. Perit Dial Int 2007;27:311-3. [Pubmed]
[38]
Böhlke M, Souza PA, Menezes AM, Roth JM, Kramer LR. Peritonitis due to Penicillium and Enterobacter in a patient receiving continuous ambulatory peritoneal dialysis. Braz J Infect Dis 2007;11:166-8. [Pubmed]
[39]
Liang CC, Fang JT, Chen KH, Hung CC, Hwang TL, Huang JY. Candida parapsilosis peritonitis complicated with infected pancreatic pseudocysts in a peritoneal dialysis patient: a challenge for nephrologists. Clin Nephrol 2008;69:461-3. [Pubmed]
[40]
Montenegro J, Aguirre R, González O, Martínez I, Saracho R. Fluconazole treatment of Candida peritonitis with delayed removal of the peritoneal dialysis catheter. Clin Nephrol 1995;44:60-3. [Pubmed]
[41]
Yuen KY, Seto WH, Ching TY, Cheung WC, Kwok Y, Chu YB. An outbreak of Candida tropicalis peritonitis in patients on intermittent peritoneal dialysis. J Hosp Infect 1992;22:65-72. [Pubmed]
[42]
Cheng VC, Lo WK, Woo PC, Chan SB, Cheng SW, Ho M, Yuen KY. Polymicrobial outbreak of intermittent peritoneal dialysis peritonitis during external wall renovation at a dialysis center. Perit Dial Int 2001;21:296-301. [Pubmed]
[43]
Mocan H, Murphy AV, Beattie TJ, McAllister TA. Fungal peritonitis in children on continuous ambulatory peritoneal dialysis. Scott Med J 1989;34:494-6. [Pubmed]
[44]
Cinar S, Nedret Koc A, Taskapan H, Dogukan A, Tokgöz B, Utas C. Case report. Candida lusitaniae peritonitis in a patient on continuous ambulatory peritoneal dialysis. Mycoses 2002;45:120-2. [Pubmed]
[45]
García-Martos P, Díaz J, Castaño M, Pérez M, Marín P. Peritonitis caused by Candida lusitaniae in patient on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1991;36:50. [Pubmed]
[46]
Tarif N. Candida lusitaniae peritonitis in a chronic ambulatory peritoneal dialysis patient. Saudi J Kidney Dis Transpl 2004;15:170-3. [Pubmed]
[47]
Mydlik M, Tkacova E, Szovenyiova K, Mizla P, Derzsiova K. Saccharomyces cerevisiae peritonitis complicating CAPD. Perit Dial Int 1996;16:188. [Pubmed]
[48]
Snyder S. Peritonitis due to Saccharomyces cerevisiae in a patient on CAPD. Perit Dial Int 1992;12:77-8. [Pubmed]
[49]
Guclu E, Soypacaci Z, Yildirim M, Kucukbayrak A, Ozdemir D. First case of continuous ambulatory peritoneal dialysis peritonitis due to Candida sake. Mycoses 2008;52:280-1. [Pubmed]
[50]
Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993;17:736-41. [Pubmed]
[51]
Mansoor GA, Ornt DB. Cryptococcal peritonitis in peritoneal dialysis patients: a case report. Clin Nephrol 1994;41:230-2. [Pubmed]
[52]
Sinott JT, Rodnite J, Emmanuel PJ, Campos A. Cryptococcus laurentii infection complicating peritoneal dialysis. Pediatr Infect Dis J 1989;8:803-5. [Pubmed]
[53]
Ujhelyi MR, Raasch RH, Van der Horst CM, Mattern WD. Treatment of peritonitis due to Curvularia and Trichosporon with amphotericin B. Rev Infect Dis 1990;12:621-7. [Pubmed]
[54]
Kouppari G, Stephanidis K, Zaphiropoulou A, Siapera D, Deliyianni V. Trichosporon beigelii peritonitis in a child on continuous ambulatory peritoneal dialysis. Clin Microbiol Infect 1997;3:509-10.
[55]
Yuen KY, Seto WH, Li KS, Leung R. Trichosporon beigelii peritonitis in continuous ambulatory peritoneal dialysis. J Infect 1990;20:178-9.
[56]
Madariaga MG, Tenorio A, Proia L. Trichosporon inkin peritonitis treated with caspofungin. J Clin Microbiol 2001;41:5827-9. [Pubmed]
[57]
Crowther KS, Webb AT, McWhinney PH. Trichosporon inkin peritonitis in a patient on continuous ambulatory peritoneal dialysis returning from the Caribbean. Clin Nephrol 2003; 59:69-70. [Pubmed]
[58]
Lopes JO, Alves SH, Klock C, Oliveira LT, Dal Forno NR. Trichosporon inkin peritonitis during continuous ambulatory peritoneal dialysis with bibliography review. Mycopathologia 1997;139:15-8. [Pubmed]
[59]
De Saedeleer B, Sennesael J, Van der Niepen P, Verbeelen D. Intraperitoneal fluconazole therapy for Trichosporon cutaneum peritonitis in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1994;9:1658-9. [Pubmed]
[60]
Jian DY, Yang WC, Chen TW, Lin CC. Trichosporon asahii following polymicrobial infection in peritoneal dialysis-associated peritonitis. Perit Dial Int 2008;28:100-1. [Pubmed]
[61]
Soylu A, Demircio¿lu F, Türkmen M, Yücesoy M, Kavukçu S. Unusual cause of peritonitis during peritoneal dialysis. Rhodotorula rubra and amphotericin B. Pediatr Nephrol 2004;19:1426-8.
[62]
Pennington JC 3rd, Hauer K, Miller W. Rhodotorula rubra peritonitis in an HIV patient on CAPD. Del Med J 1995;67:184. [Pubmed]
[63]
De Zoysa JR, Searle M, Lynn KL, Robson RA. Successful treatment of CAPD peritonitis caused by Rhodotorula mucilaginosa. Perit Dial Int 2001;21:627-8. [Pubmed]
[64]
Wood M, Roxby CM, Gould K, Martin AM. Peritonitis due to Rhodotorula glutinis in a patient on CAPD. Perit Dial Bull 1985;5:205.
[65]
Choy BY, Wong SS, Chan TM, Lai KN. Pichia ohmeri peritonitis in a patient on CAPD: response to treatment with amphotericin. Perit Dial Int 2000;20:91. [Pubmed]
[66]
Hernández Jaras J, Martínez-Martínez L, Gallego JL, Fernández Fernández J, Botella J. Geotrichum sp. as an agent of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987;28:210. [Pubmed]
[67]
Johnson AS, Bailey E, Wright PA, Solomon L. Malassezia furfur: a possible cause of culture-negative CAPD peritonitis. Perit Dial Int 1996;16:187-8. [Pubmed]
[68]
Fine A, Churchill D, Gault H, Furdy P. Pityrosporum pachydermatis peritonitis in a CAPD patient on long-term intraperitoneal antibiotics. Perit Dial Bull 1983;3:108-9.
[69]
Lopes JO, Alves SH, Benevenga JP, Regio OR, Calil A. Histoplasma capsulatum peritonitis associated with continuous ambulatory peritoneal dialysis. Mycopathologia 1993;122:101-2. [Pubmed]
[70]
Lopes JO, Alves SH, Benevenga JP, Rosa AC. The second case of peritonitis due to Histoplasma capsulatum during continuous ambulatory peritoneal dialysis in Brazil. Mycoses 1994;37:161-3. [Pubmed]
[71]
Ampel NM, White JD, Varanasi UR, Larwood TR, Van Wyck DB, Galgiani JN. Coccidioidal peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1988;11:512-4. [Pubmed]
[72]
Quirin N, Desnos-Ollivier M, Cantin JF, Valery JC, Doussy Y, Goursaud R, et al. Peritonitis due to Blastobotrys proliferans in a patient undergoing continuous ambulatory peritoneal dialysis. J Clin Microbiol 2007;45:3453-5. [Pubmed]
[73]
Ide L, De Laere E, Verlinde A, Surmont I. A case of Aspergillus fumigatus peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges. J Clin Pathol 2005;58:559. [Pubmed]
[74]
Bonfante L, Nalesso F, Cara M, Antonello A, Malagoli A, Pastori G, et al. Aspergillus fumigatus peritonitis in ambulatory peritoneal dialysis: a case report and notes on the therapeutic approach. Nephrology 2005;10:270-3. [Pubmed]
[75]
Bibashi E, Papagianni A, Kelesidis A, Antoniadou R, Papadimitriou M. Peritonitis due to Aspergillus niger in a patient on continuous ambulatory peritoneal dialysis after kidney graft rejection. Nephrol Dial Transplant 1993;8:185-7. [Pubmed]
[76]
Miles AM, Barth RH. Aspergillus peritonitis: therapy, survival, and return to peritoneal dialysis. Am J Kidney Dis 1995;26:80-3. [Pubmed]
[77]
Sridhar R, Thornley-Brown D, Shashi Kant K. Peritonitis due to Aspergillus niger: diagnostic importance of peritoneal eosinophilia. Perit Dial Int 1990;10:100-1. [Pubmed]
[78]
Nannini EC, Paphitou NI, Ostrosky-Zeichner L. Peritonitis due to Aspergillus and Zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003;46:49-54. [Pubmed]
[79]
Verghese S, Palani R, Thirunavakarasu N, Chellamma T, Pathipata P. Peritonitis due to Aspergillus terreus in a patient undergoing continuous ambulatory peritoneal dialysis. Mycoses 2008;51:174-6. [Pubmed]
[80]
Kalishian Y, Miller EB, Kagan A, Landau Z. Aspergillus terreus peritonitis in a CAPD patient: report of a case. Perit Dial Int 2004;24:93. [Pubmed]
[81]
Schwetz I, Horina J, Buzina W, Roob J, Olschewski H, Krause R. Aspergillus oryzae peritonitis in CAPD: case report and review of the literature. Am J Kidney Dis 2007;49:701-4. [Pubmed]
[82]
Chiu YL, Liaw SJ, Wu VC, Hsueh PR. Peritonitis caused by Aspergillus sydowii in a patient undergoing continuous ambulatory peritoneal dialysis. J Infect 2005;51:159-61.
[83]
Ghebremedhin B, Bluemel A, Neumann KH, Koenig B, Koenig W. Peritonitis due to Neosartorya pseudofischeri in an elderly patient undergoing peritoneal dialysis successfully treated with voriconazole. J Med Microbiol 2009;58:678-82. [Pubmed]
[84]
Matsumoto N, Shiraga H, Takahashi K, Kikuchi K, Ito K. Successful treatment of Aspergillus peritonitis in a peritoneal dialysis patient. Pediatr Nephrol 2002;17:243-5. [Pubmed]
[85]
Chang HR, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JD. Peritoneal-dialysis-associated Penicillium peritonitis. Am J Nephrol 2000;20:250-2. [Pubmed]
[86]
Huang JW, Chu TS, Wu MS, Peng YS, Hsieh BS. Visible Penicillium spp. colonization plaques on a Tenckhoff catheter without resultant peritonitis in a peritoneal dialysis patient. Nephrol Dial Transplant 2000;15:1872-3. [Pubmed]
[87]
Keceli S, Yegenaga I, Dagdelen N, Mutlu B, Uckardes H, Willke A. Case report: peritonitis by Penicillium spp. in a patient undergoing continuous ambulatory peritoneal dialysis. Int Urol Nephrol 2005;37:129-31. [Pubmed]
[88]
Kovac D, Lindic J, Lejko-Zupanc T, Bren AF, Knap B, Lesnik M, et al. Treatment of severe Paecilomyces varioti peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1998;13:2943-6. [Pubmed]
[89]
Rinaldi S, Fiscarelli E, Rizzoni G. Paecilomyces variotii peritonitis in an infant on automated peritoneal dialysis. Pediatr Nephrol 2000;14:365-6. [Pubmed]
[90]
Bibashi E, Kokolina E, Sigler L, Sofianou D, Tsakiris D, Visvardis G, et al. Three cases of uncommon fungal peritonitis in patients undergoing peritoneal dialysis. Perit Dial Int 2002;22:523-5. [Pubmed]
[91]
Wright K, Popli S, Gandhi VC, Lentino JR, Reyes CV, Leehey DJ. Paecilomyces peritonitis: case report and review of the literature. Clin Nephrol 2003;59:305-10. [Pubmed]
[92]
Chang BP, Sun PL, Huang FY, Tsai TC, Lin CC, Lee MD, et al. Paecilomyces lilacinus peritonitis complicating peritoneal dialysis cured by oral voriconazole and terbinafine combination therapy. J Med Microbiol 2008;57:1581-4. [Pubmed]
[93]
Korzets A, Weinberger M, Chagnac A, Goldschmied-Reouven A, Rinaldi MG, Sutton DA. Peritonitis due to Thermoascus taitungiacus Anamorph Paecilomyces taitungiacus. J Clin Microbiol 2001;39:720-4. [Pubmed]
[94]
Alscher DM, Pfinder-Nohe E, Rumpf D, Pauli-Magnus C, Knabbe C, Kuhlmann U, et al. Moulds in containers with biological wastes as a possible source of peritonitis in two patients on peritoneal dialysis. Perit Dial Int 1998;18:643-6. [Pubmed]
[95]
Koc N, Utas C, Oymak O, Sehmen E. Peritonitis due to Acremonium strictum in a patient on continuous ambulatory peritoneal dialysis. Nephron 1998;79:357-8. [Pubmed]
[96]
Sener AG, Yucesoy M, Senturkun S, Afsar I, Yurtsever SG, Turk M. A case of Acremonium strictum peritonitis. Med Mycol 2008;46:495-7. [Pubmed]
[97]
Lopes JO, Alves SH, Rosa AC, Silva CB, Sarturi JC, Souza CAR. Acremonium kiliense peritonitis complicating continuous ambulatory peritoneal dialysis: report of two cases. Mycopathologia 1995;131:83-5. [Pubmed]
[98]
Kendirli T, Ciftçi E, Ekim M, Galip N, Düzenli F, Ozçakar ZB, et al. Acremonium spp. peritonitis in an infant. Mycoses 2008;51:455-7. [Pubmed]
[99]
Nuño E, Cisneros JM, Regordan C, Montes R, Guerrero MA, Martín C. Peritonitis por Fusarium solani: una complicación infrecuente de la diálisis peritoneal. Enferm Infecc Microbiol Clin 1995;13:196-7. [Pubmed]
[100]
García-Tapia A, Aznar E, García-Martos P, Marín P, Márquez A, Lozano C, et al. Fusarium peritonitis in a patient on peritoneal dialysis. Rev Iberoam Micol 1999;16:166-7. [Pubmed]
[101]
Flynn JT, Meislich D, Kaiser BA, Polinsky MS, Baluarte HJ. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996;16:52-7. [Pubmed]
[102]
Giacchino F, Belardi P, Merlino C, Aimino M, Garneri G, Cuffini AM, et al. Treatment of Fusarium peritonitis in a peritoneal dialysis patient. Perit Dial Int 1997;17:403-4. [Pubmed]
[103]
Agarwal S, Goodman NL, Malluche HH. Peritonitis due to Exophiala jeanselmei in a patient undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;21:673-5. [Pubmed]
[104]
Remon C, De la Calle IJ, Vallejo Carrión F, Pérez-Ramos S, Fernández Ruiz E. Exophiala jeanselmei peritonities in a patient on CAPD. Perit Dial Int 1996;16:536-8. [Pubmed]
[105]
Lye WC. Peritonitis due to Wangiella dermatitidis in a patient on CAPD. Perit Dial Int 1993;13:319-20. [Pubmed]
[106]
Vlassopoulos D, Kouppari G, Arvanitis D, Papaefstathiou K, Dounavis A, Velegraki A, et al. Wangiella dermatitidis peritonitis in a CAPD patient. Perit Dial Int 2001;21:96-7. [Pubmed]
[107]
Greig J, Harkness M, Taylor P, Hashmi C, Liang S, Kwan J. Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis. Clin Microbiol Infect 2003;9:713-5. [Pubmed]
[108]
Lopes JO, Alves SH, Benevenga JP, Brauner FB, Castro MS, Melchiors E. Curvularia lunata peritonitis complicating peritoneal dialysis. Mycopathologia 1994;127:65-7. [Pubmed]
[109]
Pimentel JD, Mahadevan K, Woodgyer A, Sigler L, Gibas C, Harris OC, et al. Peritonitis due to Curvularia inaequalis in an elderly patient undergoing peritoneal dialysis and a review of six cases of peritonitis associated with other Curvularia spp. J Clin Microbiol 2005;43:4288-92. [Pubmed]
[110]
Vachharajani TJ, Zaman F, Latif S, Penn R, Abreo KD. Curvularia geniculata fungal peritonitis: a case report with review of literature. Int Urol Nephrol 2005;37:781-4. [Pubmed]
[111]
Canon HL, Buckingham SC, Wyatt RJ, Jones DP. Fungal peritonitis caused by Curvularia species in a child undergoing peritoneal dialysis. Pediatr Nephrol 2001;16:35-7. [Pubmed]
[112]
Vogelgesang SA, Lockard JW, Quinn MJ, Hasbargen JA. Alternaria peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1990;10:313. [Pubmed]
[113]
Reiss-Levy E, Clingan P. Peritonitis caused by Alternaria alternata. Med J Aust 1981;2:44. [Pubmed]
[114]
Bava AJ, Fayad A, Céspedes C, Sandoval M. Fungal peritonitis caused by Bipolaris spicifera. Med Mycol 2003;41:529-31. [Pubmed]
[115]
Gadallah MF, White R, El-Shahawy MA, Abreo F, Oberle A, Work J. Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Am J Nephrol 1995;15:348-52. [Pubmed]
[116]
Mise N, Ono Y, Kurita N, Sai K, Nishi T, Tagawa H, et al. Aureobasidium pullulans peritonitis: case report and review of the literature. Perit Dial Int 2008;28:679-81. [Pubmed]
[117]
Caporale NE, Calegari L, Perez D, Gezuele E. Peritoneal catheter colonization and peritonitis with Aureobasidium pullulans. Perit Dial Int 1996;16:97-8. [Pubmed]
[118]
Severo LC, Oliveira F, Garcia CD, Uhlmann A, Londero AT. Peritonitis by Scedosporium apiospermum in a patient undergoing continuous ambulatory peritoneal dialysis. Rev Inst Med Trop Sao Paulo 1999;41:263-4. [Pubmed]
[119]
Vaidya PS, Levine JF. Scopulariopsis peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1992;12:78-9. [Pubmed]
[120]
Esel D, Koc AN, Utas C, Karaca N, Bozdemir N. Fatal peritonitis due to Trichoderma sp. in a patient undergoing continuous ambulatory peritoneal dialysis. Mycoses 2003;46:71-3. [Pubmed]
[121]
Guiserix J, Ramdane M, Finielz P, Michault A, Rajaonarivelo P. Trichoderma harzianum peritonitis in peritoneal dialysis. Nephron 1996;74:473-4. [Pubmed]
[122]
Tanis BC, Van der Pijl H, Van Ogtrop ML, Kibbelaar RE, Chang PC. Fatal fungal peritonitis by Trichoderma longibrachiatum complicating peritoneal dialysis. Nephrol Dial Transplant 1995;10:114-6. [Pubmed]
[123]
Febré N, Silva V, Medeiros EA, Godoy P, Reyes E, Halker E, et al. Contamination of peritoneal dialysis fluid by filamentous fungi. Rev Iberoam Micol 1999;16:238-9. [Pubmed]
[124]
Ahmad S, Johnson RJ, Hillier S, Shelton WR, Rinaldi MG. Fungal peritonitis caused by Lecythophora mutabilis. J Clin Microbiol 1985;22:182-6. [Pubmed]
[125]
Shin JH, Lee SK, Suh SP, Ryang DW, Kim NH, Rinaldi MG, et al. Fatal Hormonema dematioides peritonitis in a patient on continuous ambulatory peritoneal dialysis: criteria for organism identification and review of other known fungal etiologic agents. J Clin Microbiol 1998;36:2157-63. [Pubmed]
[126]
Amici G, Grandesso S, Mottola A, Virga G, Teodori T, Maresca MC, et al. Verticillium peritonitis in a patient on peritoneal dialysis. Am J Nephrol 1994;14:216-9. [Pubmed]
[127]
Nayak S, Satish R, Gokulnath, Savio J, Rajalakshmi T. Peritoneal mucormycosis in a patient on CAPD. Perit Dial Int 2007;27:216-7. [Pubmed]
[128]
Nakamura M, Weil WB Jr, Kaufman DB. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine. Pediatr Nephrol 1989;3:80-2. [Pubmed]
[129]
Sedlacek M, Cotter JG, Suriawinata AA, Kaneko TM, Zuckerman RA, Parsonnet J, et al. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B. Am J Kidney Dis 2008;51:302-6. [Pubmed]
[130]
Fergie JE, Fitzwater DS, Einstein P, Leggiadro RJ. Mucor peritonitis associated with acute peritoneal dialysis. Pediatr Infect Dis J 1992;11:498-500. [Pubmed]
[131]
Pimentel JD, Dreyer G, Lum GD. Peritonitis due to Cunninghamella bertholletiae in a patient undergoing continuous ambulatory peritoneal dialysis. J Med Microbiol 2006;55:115-8. [Pubmed]
[132]
Keane W, Bailie G, Boeschoten E, Gokal R, Golper T, Holmes C, et al. ISPD guidelines/recommendations. Adult peritoneal dialysisrelated peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000;20:396-411. [Pubmed]
[133]
Scotter JM, Stevens JM, Chambers ST, Lynn KL, Patton WN. Diagnosis of Aspergillus peritonitis in a renal dialysis patient by PCR and galactomannan detection. J Clin Pathol 2004;57: 662-4. [Pubmed]
[134]
Arrieta J, Bajo MA, Caravaca F, Coronel F, García-Pérez H, González-Parra E, et al. Guías SEN. Guías de Práctica Clínica en Diálisis Peritoneal. Nefrología 2006; 26 (Supl. 4).
[135]
Boer WH, Van Ampting JM, Vos P. Successful treatment of eight episodes of Candida peritonitis without catheter removal using intracatheter administration of amphotericin B. Perit Dial Int 2007;27:208-10. [Pubmed]
[136]
Blowey DL, Garg UC, Kearns GL, Warady BA. Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis. Adv Perit Dial 1998;14:247-50. [Pubmed]
[137]
Kleinpeter MA. Successful treatment of Candida infections in peritoneal dialysis patients: case reports and review of the literature. Adv Perit Dial 2004;20:58-61. [Pubmed]
[138]
Selgas R, Cirugeda A, Sansone G. Peritonitis fúngicas en diálisis peritoneal: las nuevas soluciones pueden ser una esperanza. Nefrología 2003;23:298-9. [Pubmed]
[139]
Zaruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuos ambulatory peritoneal dialysis: six years¿ experience. Am J Kidney Dis 1991;17:43-6. [Pubmed]
[140]
Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007;27:531-6. [Pubmed]
[141]
Wadhwa NK, Suh H, Calbralda T. Antifungal prophylaxis for secundary fungal peritonitis in peritoneal dialysis patients. Adv Perit Dial 1996;12:189-95.
[142]
Moreiras-Plaza M, Vello-Román A, Sampróm-Rodríguez M, Feijóo- Piñeiro D. Ten years without fungal peritonitis: a single center¿s experience. Perit Dial Int 2007;27:460-3. [Pubmed]
[143]
Thodis E, Vas SI, Bargman JM, Singhal M, Chu M, Oreopoulos DG. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1998;18:583-9. [Pubmed]
[144]
Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 2003;8:184-91. [Pubmed]
[145]
Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006;26:405-7. [Pubmed]
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?